Pionyr Immunotherapeutics

Third Generation Cancer

Press Release

Pionyr develops drugs to perform exceptional fine-tuning of immune responses. This goal addresses a current and justified excitement about immunotherapy and introduces technology to rapidly identify and target novel arms of the immune response, within the tumor microenvironment (TME). Our programs are generating stand-alone therapies as well as combinatorial immunotherapeutics, fine-tuned to synergize at the tumor-site while minimizing effects on the patient.


415 226-7503

Mailing/FEDEX: 953 Indiana St.
San Francisco, CA 94107

View on the map